Kisho

Suzhou Zelgen Biopharmaceuticals Co.,Ltd — Rare Disease Pipeline | Kisho

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Other

Orphan Designations

0 approved, 3 designated

FDA Approvals

Active Trials

200 recruiting

Rare Diseases

across 13 areas

News (30d)

Quiet

Suzhou Zelgen Biopharmaceuticals Co.,Ltd is a company with 3 orphan drug designations across 6 rare diseases. Active clinical trials in 1 indication.

Competitive Landscape

Diversified Portfolio

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 1

Designated Only: 5

6 total diseases

Disease	Drug(s)	Stage
cellular phase chronic idiopathic myelofibrosis	Jaktinib Dihydrochloride Monohydrate	Des.TrialAppr.
cervical cancer	-	Des.TrialAppr.
essential thrombocythemia	Jaktinib Dihydrochloride Monohydrate	Des.TrialAppr.
neuroendocrine carcinoma	a trispecific antibody binding to two different epitopes on tumor antigen DLL3 and tumor antigen CD3	Des.TrialAppr.
primary myelofibrosis	Jaktinib Dihydrochloride Monohydrate	Des.TrialAppr.
small cell lung carcinoma	a trispecific antibody binding to two different epitopes on tumor antigen DLL3 and tumor antigen CD3	Des.TrialAppr.